Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1HER2-expressing Cancers 1Composite Lymphoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 59Cisplatin 45Cetuximab 29Radiotherapy 26Carboplatin 24Docetaxel 17Paclitaxel 16Nivolumab 16Surveys and Questionnaires 15Radiotherapy, Intensity-Modulated 13Fluorouracil 12Drug Therapy 12Blood Specimen Collection 11Standard of Care 8tislelizumab 7cemiplimab 6atezolizumab 6Radiation 6Chemoradiotherapy 6toripalimab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5nimotuzumab 4fludarabine 4durvalumab 4dostarlimab 4Surgical Procedures, Operative 4Afatinib 4palbociclib 3niraparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × ALX148 × 1 year × Clear all
NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

ALX Oncology Inc.

Phase 2 Active not recruiting
172 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04675294 2025-08-01

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

ALX Oncology Inc.

Phase 2 Active not recruiting
189 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡